Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 10
Submit an article Journal homepage
505
Views
61
CrossRef citations to date
0
Altmetric
Reviews

Targeting IL-6 in the treatment of inflammatory and autoimmune diseases

Changhai Ding Monash University, Central and Eastern Clinical School, Department of Epidemiology and Preventive Medicine, Commercial Road, Melbourne 3004, Australia +61 99030555; +61 990305556; [email protected]; University of Tasmania, Menzies Research Institute, Hobart, Australia
, MD,
Flavia Cicuttini Monash University, Central and Eastern Clinical School, Department of Epidemiology and Preventive Medicine, Commercial Road, Melbourne 3004, Australia +61 99030555; +61 990305556; [email protected]
, PhD,
Jun Li Anhui Medical University, School of Pharmacy, Hefei, China
, MD &
Graeme Jones University of Tasmania, Menzies Research Institute, Hobart, Australia
, MD
Pages 1457-1466 | Published online: 28 Aug 2009

Bibliography

  • Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1(3):193-200
  • Cronstein BN. Interleukin-6–a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S11-15
  • Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4-10
  • Imagawa T, Mori M, Takei S, et al. Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis. Arthritis Rheum 2006;54(9):S168-S168
  • Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5(12):1731-40
  • Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8(Suppl 2):S2
  • Ding C, Jones G. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther 2003;5(1):64-9
  • Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30(7):1426-35
  • Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29
  • Jones G, Gu JR, Lowenstein M, et al. The AMBITION study: superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2009;68:online
  • Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-50
  • Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(6):1761-9
  • Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66(9):1162-7
  • Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-9
  • Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008 [Epub ahead of print]
  • Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97
  • Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
  • Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
  • Emery P, Keystone E, Tony HP, et al. Patients achieve significant improvement in rheumatoid arthritis (RA) outcomes with tociluzumab (TCZ) regardless of prior inadequate response (IR) to TNF antagonists. Arthritis Rheum 2008;58(9):S533-S533
  • Kremer JM, Fleischmann RM, Halland AM, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. Arthritis Rheum 2008;58(12):4031-4031
  • Gamero P, Mareau E, Thompson L, Woodworth T. The anti-IL6 receptor inhibitor tocilizumab (TCZ) combined with methotrexate (MTX) induces a rapid and sustained decrease of bone and cartilage degradation in patients with rheumatoid arthritis (RA). Arthritis Rheum 2008;58(9):S534-S534
  • Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7(6):R1281-8
  • Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52(3):818-25
  • Yokota S, Miyamae T, Kurosawa R, et al. Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra (R)). Arthritis Rheum 2005;52(9):S725-S725
  • Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998-1006
  • Yokota S, Imagawa T, Miyamae T, et al. Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials. Arthritis Rheum 2008;58(9):S631-2
  • Inaba Y, Ozawal R, Imagawa T, et al. Radiologic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following treatment with tocilizumab, anti-IL 6 receptor monoclonal antibody. Ann Rheum Dis 2007;66:550-1
  • Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8):2627-32
  • Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95(1):56-61
  • Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126(4):989-96; discussion 947
  • Shirota Y, Yarboro C, Sims G, et al. The impact of in vivo anti IL-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(9):S697-S697
  • Illei GG, Yarboro C, Shirota Y, et al. Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Arthritis Rheum 2006;54(12):4043-4043
  • Smolen JS, Beaulieu AD, Dikranian A, et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S784-S784
  • Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 2006;65(12):1667-9
  • van Vollenhoven RF, Smolen J, Tony HPT, et al. Safety of tocilizumab in patients with rheumatoid arthritis: an interim analysis of long-term extension trials with a mean treatment duration of 1.5 years. Arthritis Rheum 2008;58(9):S784-5
  • Kremer JM, van Vollenhoven RF, Ridley DJ, et al. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years. Arthritis Rheum 2008;58(9):S783-4
  • Kremer JM, Joh AK, Malamet R, Keystone EC. Hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S783-S783
  • Genovese MC, Smolen JS, Emery P, et al. Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S531-2
  • Genovese MC, Smolen JS, Emery P, et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S785-6
  • Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8(1):75-9
  • Ramos-Remus C, Genovese MC, Harre RA, et al. Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: analysis of four phase 3 clinical trials. Arthritis Rheum 2008;58(9):S534-S534
  • Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 2008;26(9):957-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.